Arup Roy
Directeur/Membre du Conseil chez Seraxis Holdings, Inc.
Profil
Arup Roy has worked as a Director at Seraxis, Inc. and Seraxis Holdings, Inc. He has no middle name and his full name is Mr. Roy.
Postes actifs de Arup Roy
Sociétés | Poste | Début |
---|---|---|
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Directeur/Membre du Conseil | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Finance |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Health Technology |